stockrowEntrada Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
- Revenue
- −43.9%
- EPS
- +11.3%
- Free cash flow
- −7.05%
Quarter to September 2026, against a year earlier
Follow TRDA
Alert me
Entrada Therapeutics, Inc. (TRDA) EV/Sales
As of 6 November 2026, Entrada Therapeutics, Inc. (TRDA) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −3.2× (May 2026) to 72.5× (May 2026); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | 375.11% |
| FY2024 | 1.1× | (7.81%) |
| FY2023 | 1.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 19.1× | 2.15% |
| Jun 2026 | 18.7× | (60.66%) |
| Mar 2026 | 47.6× | 838.38% |
| Dec 2025 | 5.1× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −26.9× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −2.3× |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IVVD Invivyd, Inc. compare | 0.3× |
| CGEN Compugen Ltd. compare | 0.8× |
| WHWK Whitehawk Therapeutics, Inc. compare | 2.5× |
| TRDA Entrada Therapeutics, Inc. | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| MDWD MediWound Ltd. compare | 12.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)